Brand name: Minimed 670G System
Device Generic Name: Automated Insulin Delivery System
Device class: Insulin Pump
FDA Approval date: September 28, 2016
On September 28th, 2016, the US Food and Drug Administration approved MiniMed 670G by Medtronic. It is the first FDA-approved device that automatically monitors glucose levels while providing an appropriate basal insulin dose in type 1 diabetics older than 14 years.
What is the MiniMed 670G used to treat?
MiniMed 670G is a hybrid closed looped system approved by the FDA to treat type 1 diabetes patients ages 14 years or older who require greater than 8 units of basal insulin per day.
What is Minimed 670G and how does it work?
MiniMed 670G has an integrated SmartGuard technology with an advanced algorithm to simplify and improve diabetes management. It enables greater glucose control with reduced user input. The system includes:
The glucose sensor is inserted under the skin of the abdomen and it measures glucose values in the tissue fluid. The sensor measures blood glucose levels every 5 minutes (interval depends on settings) and the insulin pump automatically administers or withholds basal insulin depending on blood glucose levels and user selected insulin dosing rates. If the glucose level is higher than the preset normal range, then insulin will be delivered following the algorithm. If the glucose level is lower than the preset normal range, the device will withhold insulin administration. Although the device works automatically, the user can also` administer insulin manually to adjust for meals. The MiniMed 670G delivers at least 8 units per day of rapid acting insulin.
What are possible side effects of the MiniMed 670G?
Potential adverse effects from the device include: